HOUSTON and VANCOUVER, BC, Nov. 25,
2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA"
or the "Company"), a clinical-stage pharmaceutical company focused
on developing novel therapies for the treatment of prostate cancer
announced the Company will be presenting at the Evercore ISI
3rd Annual HealthCONx Conference.
Dr. David. R. Parkinson, Chief Executive Officer, will present a
corporate overview of the Company's business. Dr. Parkinson
along with ESSA's Chief Operating Officer, Peter Virsik, and Chief Financial Officer,
David S. Wood will be available for
one-on-one meetings from December 1 -
3, 2020.
The presentations will be webcast live and can be accessed
through the Investor Relations page at www.essapharma.com. A
replay of the presentations will be available on the Company's
website for 90 days.
Evercore ISI 3rd Annual HealthCONx
Conference
Presentation
Date: Thursday December 3,
2020
Presentation Time: 9:10am Pacific / 12:10pm Eastern
About ESSA Pharma Inc.
ESSA is a clinical-stage
pharmaceutical company focused on developing novel and proprietary
therapies for the treatment of castration-resistant prostate cancer
in patients whose disease is progressing despite treatment with
current therapies. The Company filed an IND with the U.S. Food and
Drug Administration for EPI-7386 in the first calendar quarter of
2020 and clearance was received April
30,2020. A Clinical Trial Application was filed with Health
Canada in April 2020 and
authorization was received June
3rd, 2020. For more information, please visit
www.essapharma.com and follow us on Twitter under
@ESSAPharma.
About Prostate Cancer
Prostate cancer is the
second-most commonly diagnosed cancer among men and the fifth most
common cause of male cancer death worldwide (Globocan, 2018).
Adenocarcinoma of the prostate is dependent on androgen for tumor
progression and depleting or blocking androgen action has been a
mainstay of hormonal treatment for over six decades. Although
tumors are often initially sensitive to medical or surgical
therapies that decrease levels of testosterone, disease progression
despite castrate levels of testosterone generally represents a
transition to the lethal variant of the disease, mCRPC, and most
patients ultimately succumb to the illness. The treatment of mCRPC
patients has evolved rapidly over the past five years. Despite
these advances, additional treatment options are needed to improve
clinical outcomes in patients, particularly those who fail existing
treatments including abiraterone or enzalutamide, or those who have
contraindications to receive those drugs. Over time, patients with
mCRPC generally experience continued disease progression, worsening
pain, leading to substantial morbidity and limited survival rates.
In both in vitro and in vivo animal studies, ESSA's novel approach
to blocking the androgen pathway has been shown to be effective in
blocking tumor growth when current therapies are no longer
effective.
Forward-Looking Statement
Disclaimer
This release contains certain
information which, as presented, constitutes "forward-looking
information" within the meaning of the Private Securities
Litigation Reform Act of 1995 and/or applicable Canadian securities
laws. Forward-looking information involves statements that relate
to future events and often addresses expected future business and
financial performance, containing words such as "anticipate",
"believe", "plan", "estimate", "expect", and "intend", statements
that an action or event "may", "might", "could", "should", or
"will" be taken or occur, or other similar expressions and
includes, but is not limited to, the belief that the Company is on
a solid path to complete the Phase 1 dose escalation, expansion,
and combination studies as planned, timing and enrollment of
a Phase 1 study of EPI-7386, other statements surrounding the
Company's clinical evaluation of EPI-7386, the funds from the
recent financing supporting multiple combination studies with
existing anti-androgen drugs, and the Company's current cash
reserves.
Forward-looking statements and information are subject to
various known and unknown risks and uncertainties, many of which
are beyond the ability of ESSA to control or predict, and which may
cause ESSA's actual results, performance or achievements to be
materially different from those expressed or implied thereby. Such
statements reflect ESSA's current views with respect to future
events, are subject to risks and uncertainties and are necessarily
based upon a number of estimates and assumptions that, while
considered reasonable by ESSA as of the date of such statements,
are inherently subject to significant medical, scientific,
business, economic, competitive, political and social uncertainties
and contingencies. In making forward looking statements, ESSA may
make various material assumptions, including but not limited to (i)
the accuracy of ESSA's financial projections; (ii) obtaining
positive results of clinical trials; (iii) obtaining necessary
regulatory approvals; and (iv) general business, market and
economic conditions.
Forward-looking information is developed based on assumptions
about such risks, uncertainties and other factors set out herein
and in ESSA's Annual Report on Form 20-F dated December 19, 2019 under the heading "Risk
Factors", a copy of which is available on ESSA's profile on the
SEDAR website at www.sedar.com, ESSA's profile on EDGAR at
www.sec.gov, and as otherwise disclosed from time to time on ESSA's
SEDAR profile. Forward-looking statements are made based on
management's beliefs, estimates and opinions on the date that
statements are made and ESSA undertakes no obligation to update
forward-looking statements if these beliefs, estimates and opinions
or other circumstances should change, except as may be required by
applicable Canadian and United
States securities laws. Readers are cautioned against
attributing undue certainty to forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
View original
content:http://www.prnewswire.com/news-releases/essa-pharma-to-participate-at-evercore-isi-3rd-annual-healthconx-conference-301180096.html
SOURCE ESSA Pharma Inc